// App-Quantinova.ai

1939 : Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Researchers

Presenter

  • Hind Rafei

Principal Investigators

  • Koji Sasaki

  • Nicholas J. Short

  • Farhad Ravandi

  • Xuelin Huang

  • Joseph D. Khoury

  • Sa A Wang

  • Jeffrey L. Jorgensen

  • C. Cameron Yin

  • Issa F. Khouri

  • Partow Kebriaei

  • Nitin Jain

  • Koichi Takahashi

  • Bouthaina S. Dabaja

  • Srdan Verstovsek

  • Tapan M. Kadia

  • Shilpa Paul

  • Caitlin R. Rausch

  • Guillermo Garcia-Manero

  • William G. Wierda

  • Courtney D. DiNardo

  • Naval Daver

  • Guillermo Montalban-Bravo

  • Musa Yilmaz

  • Patrice Nasnas

  • Rita Khouri

  • Monica Kwari

  • Jovitta Jacob

  • Meagan Rostykus

  • Rebecca Garris

  • Marina Konopleva

  • Susan M. O'Brien

  • Elias Jabbour

Medical Centers

  • 1.MD Anderson Cancer Center, Houston, TX

  • Department of Leukemia, Professor and Chairman, Department of Leukemia, Samsung Distinguished University Chair in Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Associate Professor of Medicine Department of Leukemia The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Lymphoma, MD anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Genetics, UT MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • UCI Cancer Center, Orange, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Blinatumomab

  • Methotrexate

  • Cytarabine liposomal

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved